Pub Date : 2026-01-07DOI: 10.1093/eurheartj/ehaf1061
Filippo Crea
{"title":"Focus on arrhythmias: cardiac endogenous transmitter systems, atrial fibrillation, and short QT and Brugada syndromes.","authors":"Filippo Crea","doi":"10.1093/eurheartj/ehaf1061","DOIUrl":"https://doi.org/10.1093/eurheartj/ehaf1061","url":null,"abstract":"","PeriodicalId":11976,"journal":{"name":"European Heart Journal","volume":"82 1","pages":"139-144"},"PeriodicalIF":39.3,"publicationDate":"2026-01-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145907753","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-01-07DOI: 10.1093/eurheartj/ehaf832
Marie R Schubert, Moritz F Sinner
{"title":"Understanding atrial cardiomyopathy: a missing link in the prevention of atrial fibrillation, heart failure, and stroke?","authors":"Marie R Schubert, Moritz F Sinner","doi":"10.1093/eurheartj/ehaf832","DOIUrl":"10.1093/eurheartj/ehaf832","url":null,"abstract":"","PeriodicalId":11976,"journal":{"name":"European Heart Journal","volume":" ","pages":"247-249"},"PeriodicalIF":35.6,"publicationDate":"2026-01-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145476688","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-01-07DOI: 10.1093/eurheartj/ehaf895
Eslam Samaha, Ryota Kakizaki, Jonas Dominik Häner
{"title":"Spontaneous coronary artery dissection of the septal branch: where only micro-catheter-based optical coherence tomography can prove intramural haematoma.","authors":"Eslam Samaha, Ryota Kakizaki, Jonas Dominik Häner","doi":"10.1093/eurheartj/ehaf895","DOIUrl":"10.1093/eurheartj/ehaf895","url":null,"abstract":"","PeriodicalId":11976,"journal":{"name":"European Heart Journal","volume":" ","pages":"275"},"PeriodicalIF":35.6,"publicationDate":"2026-01-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145539653","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-01-07DOI: 10.1093/eurheartj/ehaf563
Louise Segan, Peter M Kistler, Shane Nanayakkara, Andrew Taylor, James Hare, Benedict Costello, David Chieng, Rose Crowley, Jeremy William, Hariharan Sugumar, Kenneth Cho, Aleksandr Voskoboinik, Liang-Han Ling, Ziporah Nderitu, Sonia Azzopardi, Annie Curtin, Manuja Premaratne, Alex J McLellan, Justin Mariani, Joseph B Morton, Geoffrey Lee, Stephen Joseph, Christopher Reid, David M Kaye, Jonathan M Kalman, Sandeep Prabhu
Background and aims: Atrial fibrillation-mediated cardiomyopathy (AFCM) represents an important reversible cause of left ventricular systolic dysfunction. Current clinical practice is indefinite heart failure (HF) pharmacotherapy despite left ventricular ejection fraction (LVEF) normalization. However, whether this is necessary to maintain normal LVEF, in addition to rhythm control, is uncertain.
Methods: This multi-centre, randomized trial conducted between 2021 and 2024 examined the impact of staged withdrawal of HF therapy following AF rhythm control and LVEF normalization in AFCM. Participants were randomized (1:1) to early withdrawal (Group A) or continued therapy for 6 months followed by delayed withdrawal (Group B), in a crossover design. The primary endpoint was the randomized comparison of cardiac magnetic resonance (CMR) LVEF maintenance ≥50% at 6 months, during which time Group A had withdrawn therapy and Group B remained on treatment. Secondary outcomes included cardiac remodelling, functional status, biomarkers, quality of life, and arrhythmia recurrence on vs off HF therapy. The total follow-up duration was 12 months.
Results: Between July 2021 and May 2024, 60 patients were enrolled (age 60 [55-65] years, previous persistent AF <1 year and maintaining sinus rhythm for minimum 6 months following AF rhythm control [catheter ablation in 97%]). All participants completed treatment withdrawal and 12-month follow-up. In the initial randomized comparison, LVEF was maintained ≥50% at 6 months in 90% of participants undergoing HF therapy withdrawal (Group A), compared with 100% who continued medical therapy (Group B) (odds ratio [OR] 1.18, 95% confidence interval [CI] 0.27-2.82, P = .47). CMR LVEF was similar between randomization groups at the end of the randomization phase (Group A: LVEF 58% [95% CI 54-60] vs Group B: LVEF 59% [95% CI 55-64], P = .236) and across study time points (mixed effects P = .37). Transthoracic echocardiography characteristics, N-terminal pro-B-type natriuretic peptide, functional status, quality of life and AF burden were similar on vs off HF therapy in the overall population.
Conclusions: Withdrawal of HF therapy following AF rhythm control for prior AFCM and recovered LVEF was not associated with a decline in LVEF for most patients in the following 6 months.
{"title":"Withdrawal of heart failure therapy after atrial fibrillation rhythm control with ejection fraction normalization: the WITHDRAW-AF trial.","authors":"Louise Segan, Peter M Kistler, Shane Nanayakkara, Andrew Taylor, James Hare, Benedict Costello, David Chieng, Rose Crowley, Jeremy William, Hariharan Sugumar, Kenneth Cho, Aleksandr Voskoboinik, Liang-Han Ling, Ziporah Nderitu, Sonia Azzopardi, Annie Curtin, Manuja Premaratne, Alex J McLellan, Justin Mariani, Joseph B Morton, Geoffrey Lee, Stephen Joseph, Christopher Reid, David M Kaye, Jonathan M Kalman, Sandeep Prabhu","doi":"10.1093/eurheartj/ehaf563","DOIUrl":"10.1093/eurheartj/ehaf563","url":null,"abstract":"<p><strong>Background and aims: </strong>Atrial fibrillation-mediated cardiomyopathy (AFCM) represents an important reversible cause of left ventricular systolic dysfunction. Current clinical practice is indefinite heart failure (HF) pharmacotherapy despite left ventricular ejection fraction (LVEF) normalization. However, whether this is necessary to maintain normal LVEF, in addition to rhythm control, is uncertain.</p><p><strong>Methods: </strong>This multi-centre, randomized trial conducted between 2021 and 2024 examined the impact of staged withdrawal of HF therapy following AF rhythm control and LVEF normalization in AFCM. Participants were randomized (1:1) to early withdrawal (Group A) or continued therapy for 6 months followed by delayed withdrawal (Group B), in a crossover design. The primary endpoint was the randomized comparison of cardiac magnetic resonance (CMR) LVEF maintenance ≥50% at 6 months, during which time Group A had withdrawn therapy and Group B remained on treatment. Secondary outcomes included cardiac remodelling, functional status, biomarkers, quality of life, and arrhythmia recurrence on vs off HF therapy. The total follow-up duration was 12 months.</p><p><strong>Results: </strong>Between July 2021 and May 2024, 60 patients were enrolled (age 60 [55-65] years, previous persistent AF <1 year and maintaining sinus rhythm for minimum 6 months following AF rhythm control [catheter ablation in 97%]). All participants completed treatment withdrawal and 12-month follow-up. In the initial randomized comparison, LVEF was maintained ≥50% at 6 months in 90% of participants undergoing HF therapy withdrawal (Group A), compared with 100% who continued medical therapy (Group B) (odds ratio [OR] 1.18, 95% confidence interval [CI] 0.27-2.82, P = .47). CMR LVEF was similar between randomization groups at the end of the randomization phase (Group A: LVEF 58% [95% CI 54-60] vs Group B: LVEF 59% [95% CI 55-64], P = .236) and across study time points (mixed effects P = .37). Transthoracic echocardiography characteristics, N-terminal pro-B-type natriuretic peptide, functional status, quality of life and AF burden were similar on vs off HF therapy in the overall population.</p><p><strong>Conclusions: </strong>Withdrawal of HF therapy following AF rhythm control for prior AFCM and recovered LVEF was not associated with a decline in LVEF for most patients in the following 6 months.</p>","PeriodicalId":11976,"journal":{"name":"European Heart Journal","volume":" ","pages":"250-262"},"PeriodicalIF":35.6,"publicationDate":"2026-01-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12777703/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144882460","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-01-06DOI: 10.1093/eurheartj/ehaf924
Min Chul Kim,Joon Ho Ahn,Dae Young Hyun,Yongwhan Lim,Kyung Hoon Cho,Seung Hun Lee,Seongho Park,Seok Oh,Doo Sun Sim,Young Joon Hong,Ju Han Kim,Myung Ho Jeong,Jang Hyun Cho,Sang-Rok Lee,Dong Oh Kang,Jin-Yong Hwang,Young Jin Youn,Jung-Hee Lee,Young-Hoon Jeong,Jong-Hwa Ahn,Dong-Bin Kim,Eun Ho Choo,Chan Joon Kim,Weon Kim,Jay Young Rhew,Jong-Il Park,Sang-Yong Yoo,Youngkeun Ahn
BACKGROUND AND AIMSThe optimal timing of complete revascularization in patients with ST-segment elevation myocardial infarction (STEMI) and multivessel disease complicated by heart failure remains uncertain.METHODSThe OPTION-STEMI (Optimal Timing of Fractional Flow Reserve-Guided Complete Revascularization for Non-Infarct-Related Artery in ST-segment Elevation Myocardial Infarction with Multivessel Disease) trial compared immediate vs staged complete revascularization during the index admission in patients with STEMI and multivessel disease. In the OPTION-STEMI trial, immediate complete revascularization was not found to be non-inferior for the primary endpoint compared with staged complete revascularization. Pre-specified subgroup analysis was performed according to heart failure at admission, defined as Killip class II or III. The primary endpoint was a composite of death from any cause, non-fatal myocardial infarction, or any unplanned revascularization at 1 year.RESULTSAmong 994 randomized patients, 329 (33.1%) had heart failure at admission. These patients had a higher risk of primary endpoint than those without heart failure (18.2% vs 8.7%; adjusted HR 1.63; 95% CI 1.11-2.40; P = .013). At 1 year, immediate complete revascularization was associated with a higher incidence of the primary endpoint than staged complete revascularization in patients with heart failure (22.8% vs 13.3%; HR 1.79; 95% CI 1.05-3.04), but not in those without heart failure (8.0% vs 9.5%; HR 0.84; 95% CI .50-1.40). A significant interaction was observed between heart failure status and randomized strategy (P = .043).CONCLUSIONSIn the OPTION-STEMI trial, among patients with STEMI and multi-vessel disease who were not in cardiogenic shock, immediate complete revascularization was not non-inferior compared with staged complete revascularization. However, subgroup analysis suggests that the worse outcomes with immediate complete revascularization may be limited to patients with heart failure at admission. Further studies are required to demonstrate the non-inferiority of immediate complete revascularization compared with staged complete revascularization in patients without heart failure.
背景和目的st段抬高型心肌梗死（STEMI）和多血管疾病合并心力衰竭患者完全血运重建术的最佳时机仍不确定。方法OPTION-STEMI （st段抬高型心肌梗死合并多血管疾病的非梗死相关动脉分流血流储备引导完全血运重建的最佳时机）试验比较STEMI合并多血管疾病患者入院时立即与分期完全血运重建。在OPTION-STEMI试验中，与分期完全血运重建术相比，立即完全血运重建术在主要终点上并不是不逊色的。根据入院时心衰进行预先指定的亚组分析，定义为Killip II级或III级。主要终点是1年内任何原因死亡、非致死性心肌梗死或任何计划外血运重建术的复合终点。结果994例随机患者中，329例（33.1%）在入院时发生心力衰竭。这些患者的主要终点风险高于无心力衰竭患者（18.2% vs 8.7%；调整后危险比1.63;95% CI 1.11-2.40; P = 0.013）。1年后，心力衰竭患者立即完全血运重建术的主要终点发生率高于分阶段完全血运重建术（22.8% vs 13.3%; HR 1.79; 95% CI 1.05-3.04），但在无心力衰竭患者中没有（8.0% vs 9.5%; HR 0.84; 95% CI 0.50 -1.40）。在心力衰竭状态和随机化策略之间观察到显著的相互作用（P = 0.043）。结论在OPTION-STEMI试验中，在STEMI合并多血管疾病且未发生心源性休克的患者中，与分期完全血运重建术相比，立即完全血运重建术的效果并不差。然而，亚组分析表明，立即完全血运重建术的不良结果可能仅限于入院时心力衰竭的患者。需要进一步的研究来证明立即完全血运重建术与分阶段完全血运重建术在无心力衰竭患者中的非劣效性。
{"title":"Complete revascularization timing in ST-segment elevation myocardial infarction and multivessel disease with heart failure: the OPTION-STEMI trial.","authors":"Min Chul Kim,Joon Ho Ahn,Dae Young Hyun,Yongwhan Lim,Kyung Hoon Cho,Seung Hun Lee,Seongho Park,Seok Oh,Doo Sun Sim,Young Joon Hong,Ju Han Kim,Myung Ho Jeong,Jang Hyun Cho,Sang-Rok Lee,Dong Oh Kang,Jin-Yong Hwang,Young Jin Youn,Jung-Hee Lee,Young-Hoon Jeong,Jong-Hwa Ahn,Dong-Bin Kim,Eun Ho Choo,Chan Joon Kim,Weon Kim,Jay Young Rhew,Jong-Il Park,Sang-Yong Yoo,Youngkeun Ahn","doi":"10.1093/eurheartj/ehaf924","DOIUrl":"https://doi.org/10.1093/eurheartj/ehaf924","url":null,"abstract":"BACKGROUND AND AIMSThe optimal timing of complete revascularization in patients with ST-segment elevation myocardial infarction (STEMI) and multivessel disease complicated by heart failure remains uncertain.METHODSThe OPTION-STEMI (Optimal Timing of Fractional Flow Reserve-Guided Complete Revascularization for Non-Infarct-Related Artery in ST-segment Elevation Myocardial Infarction with Multivessel Disease) trial compared immediate vs staged complete revascularization during the index admission in patients with STEMI and multivessel disease. In the OPTION-STEMI trial, immediate complete revascularization was not found to be non-inferior for the primary endpoint compared with staged complete revascularization. Pre-specified subgroup analysis was performed according to heart failure at admission, defined as Killip class II or III. The primary endpoint was a composite of death from any cause, non-fatal myocardial infarction, or any unplanned revascularization at 1 year.RESULTSAmong 994 randomized patients, 329 (33.1%) had heart failure at admission. These patients had a higher risk of primary endpoint than those without heart failure (18.2% vs 8.7%; adjusted HR 1.63; 95% CI 1.11-2.40; P = .013). At 1 year, immediate complete revascularization was associated with a higher incidence of the primary endpoint than staged complete revascularization in patients with heart failure (22.8% vs 13.3%; HR 1.79; 95% CI 1.05-3.04), but not in those without heart failure (8.0% vs 9.5%; HR 0.84; 95% CI .50-1.40). A significant interaction was observed between heart failure status and randomized strategy (P = .043).CONCLUSIONSIn the OPTION-STEMI trial, among patients with STEMI and multi-vessel disease who were not in cardiogenic shock, immediate complete revascularization was not non-inferior compared with staged complete revascularization. However, subgroup analysis suggests that the worse outcomes with immediate complete revascularization may be limited to patients with heart failure at admission. Further studies are required to demonstrate the non-inferiority of immediate complete revascularization compared with staged complete revascularization in patients without heart failure.","PeriodicalId":11976,"journal":{"name":"European Heart Journal","volume":"1 1","pages":""},"PeriodicalIF":39.3,"publicationDate":"2026-01-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145907551","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-01-06DOI: 10.1093/eurheartj/ehaf1063
Kathrin A Stilz,Vincent Elvin Leonard,David Rodriguez Morales,Simone-Franziska Glaser,Veronica Larcher,Mariano Ruz Jurado,Pedro Felipe Malacarne,Nivethitha Manickam,Lukas S Tombor,Wesley T Abplanalp,Josefine Panthel,Haris Kujundzic,Ariane Fischer,Katja Schmitz,Oliver J Müller,Susanne Hille,Christian Kupatt,Tarik Bozoglu,Haider Sami,Manfred Ogris,Tara Procida-Kowalski,Marek Bartkuhn,David John,Michail Yekelchyk,Tessa Schmachtel,Michael Rieger,Minh-Duc Pham,Jaya Krishnan,Stefan Günther,Ralf P Brandes,Thomas Braun,Andreas M Zeiher,Julian U G Wagner,Stefanie Dimmeler
BACKGROUND AND AIMSAging significantly increases the risk of cardiovascular disease, characterized by progressive cardiac dysfunction. The vascular niche is crucial for maintaining cardiac homeostasis, yet endothelial cell (EC) impairment during aging remains poorly understood. This study investigates epigenetically regulated mechanisms underlying EC-dependent cardiac aging and identifies a critical role for zinc finger and BTB domain-containing protein 16 (ZBTB16).METHODSChromatin accessibility (snATAC-seq) and transcriptomic (snRNA-seq) analyses of aged hearts were performed to define age-related regulatory changes. Functional studies using genetic models were performed to assess cardiac aging phenotypes. In vitro assays examined EC senescence, secretory profiles, and effects of ZBTB16-deficient EC supernatants on fibroblasts, cardiomyocytes, and neurons. Overexpression experiments in vitro and in vivo tested whether ZBTB16 mitigates aging-associated dysfunction.RESULTSAged hearts exhibited decreased chromatin accessibility and reduced ZBTB16 expression in both humans and mice. Zbtb16 deletion in young mice, including Zbtb16-haploinsufficient and endothelial-specific knockout mice, led to premature aging, diastolic dysfunction, and increased secretion of pro-fibrotic and inflammatory factors. ZBTB16-deficient EC supernatants activated fibroblasts, induced cardiomyocyte hypertrophy, and impaired neuronal sprouting. Overexpression of ZBTB16 reversed these effects in senescent ECs and aged mice and reduced diastolic dysfunction. Mechanistic studies identified nuclear receptor-interacting protein 1 as a downstream target suppressed by ZBTB16, thereby limiting fibroblast activation and pro-fibrotic signalling.CONCLUSIONSZBTB16 preserves endothelial integrity and vascular niche homeostasis, protecting against aging-associated cardiac dysfunction. Its loss promotes EC senescence and fibrosis, whereas restoring its expression may represent a therapeutic strategy to improve cardiac function and reduce cardiovascular disease risk during aging.
{"title":"Endothelial ZBTB16: a molecular shield against cardiac aging.","authors":"Kathrin A Stilz,Vincent Elvin Leonard,David Rodriguez Morales,Simone-Franziska Glaser,Veronica Larcher,Mariano Ruz Jurado,Pedro Felipe Malacarne,Nivethitha Manickam,Lukas S Tombor,Wesley T Abplanalp,Josefine Panthel,Haris Kujundzic,Ariane Fischer,Katja Schmitz,Oliver J Müller,Susanne Hille,Christian Kupatt,Tarik Bozoglu,Haider Sami,Manfred Ogris,Tara Procida-Kowalski,Marek Bartkuhn,David John,Michail Yekelchyk,Tessa Schmachtel,Michael Rieger,Minh-Duc Pham,Jaya Krishnan,Stefan Günther,Ralf P Brandes,Thomas Braun,Andreas M Zeiher,Julian U G Wagner,Stefanie Dimmeler","doi":"10.1093/eurheartj/ehaf1063","DOIUrl":"https://doi.org/10.1093/eurheartj/ehaf1063","url":null,"abstract":"BACKGROUND AND AIMSAging significantly increases the risk of cardiovascular disease, characterized by progressive cardiac dysfunction. The vascular niche is crucial for maintaining cardiac homeostasis, yet endothelial cell (EC) impairment during aging remains poorly understood. This study investigates epigenetically regulated mechanisms underlying EC-dependent cardiac aging and identifies a critical role for zinc finger and BTB domain-containing protein 16 (ZBTB16).METHODSChromatin accessibility (snATAC-seq) and transcriptomic (snRNA-seq) analyses of aged hearts were performed to define age-related regulatory changes. Functional studies using genetic models were performed to assess cardiac aging phenotypes. In vitro assays examined EC senescence, secretory profiles, and effects of ZBTB16-deficient EC supernatants on fibroblasts, cardiomyocytes, and neurons. Overexpression experiments in vitro and in vivo tested whether ZBTB16 mitigates aging-associated dysfunction.RESULTSAged hearts exhibited decreased chromatin accessibility and reduced ZBTB16 expression in both humans and mice. Zbtb16 deletion in young mice, including Zbtb16-haploinsufficient and endothelial-specific knockout mice, led to premature aging, diastolic dysfunction, and increased secretion of pro-fibrotic and inflammatory factors. ZBTB16-deficient EC supernatants activated fibroblasts, induced cardiomyocyte hypertrophy, and impaired neuronal sprouting. Overexpression of ZBTB16 reversed these effects in senescent ECs and aged mice and reduced diastolic dysfunction. Mechanistic studies identified nuclear receptor-interacting protein 1 as a downstream target suppressed by ZBTB16, thereby limiting fibroblast activation and pro-fibrotic signalling.CONCLUSIONSZBTB16 preserves endothelial integrity and vascular niche homeostasis, protecting against aging-associated cardiac dysfunction. Its loss promotes EC senescence and fibrosis, whereas restoring its expression may represent a therapeutic strategy to improve cardiac function and reduce cardiovascular disease risk during aging.","PeriodicalId":11976,"journal":{"name":"European Heart Journal","volume":"149 1","pages":""},"PeriodicalIF":39.3,"publicationDate":"2026-01-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145907553","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-01-06DOI: 10.1093/eurheartj/ehaf1052
Anna Gvozdeva,Vadim Zakiev,Oxana Ushakova
{"title":"The beneficial effect of heart rate-lowering therapy on mortality in post-myocardial infarction patients across the treatment eras.","authors":"Anna Gvozdeva,Vadim Zakiev,Oxana Ushakova","doi":"10.1093/eurheartj/ehaf1052","DOIUrl":"https://doi.org/10.1093/eurheartj/ehaf1052","url":null,"abstract":"","PeriodicalId":11976,"journal":{"name":"European Heart Journal","volume":"14 1","pages":""},"PeriodicalIF":39.3,"publicationDate":"2026-01-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145907559","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-01-06DOI: 10.1093/eurheartj/ehaf1070
Rocco Vergallo,Carlo Patrono
{"title":"Weekly Journal Scan: In search for the optimal DAPT duration after percutaneous coronary intervention in patients with or without high bleeding risk.","authors":"Rocco Vergallo,Carlo Patrono","doi":"10.1093/eurheartj/ehaf1070","DOIUrl":"https://doi.org/10.1093/eurheartj/ehaf1070","url":null,"abstract":"","PeriodicalId":11976,"journal":{"name":"European Heart Journal","volume":"38 1","pages":""},"PeriodicalIF":39.3,"publicationDate":"2026-01-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145907550","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-01-06DOI: 10.1093/eurheartj/ehaf1077
Michaella Alexandrou,Yader Sandoval,Fernando Alfonso,Emmanouil S Brilakis
The clinical manifestations and management of obstructive epicardial coronary artery disease vary across acute (acute coronary syndromes) and chronic (chronic coronary syndromes) settings, each with distinct benefits and risks. Most acute occlusions require emergent revascularization to prevent myocardial damage and reduce the risk for major adverse cardiovascular events. Conversely, most symptomatic chronic occlusions are treated with guideline-directed medical therapy while revascularization is reserved to provide symptom relief in those with refractory symptoms despite medical therapy. Subacute coronary occlusions (SCOs), a group that historically has not been well defined, are positioned in the grey zone between these extremes, yet pose significant clinical challenges and require case-by-case assessment. This review explores the nuances of managing SCOs, highlighting the importance of tailored strategies for each clinical context.
{"title":"Subacute coronary artery occlusion: complexities of the grey zone.","authors":"Michaella Alexandrou,Yader Sandoval,Fernando Alfonso,Emmanouil S Brilakis","doi":"10.1093/eurheartj/ehaf1077","DOIUrl":"https://doi.org/10.1093/eurheartj/ehaf1077","url":null,"abstract":"The clinical manifestations and management of obstructive epicardial coronary artery disease vary across acute (acute coronary syndromes) and chronic (chronic coronary syndromes) settings, each with distinct benefits and risks. Most acute occlusions require emergent revascularization to prevent myocardial damage and reduce the risk for major adverse cardiovascular events. Conversely, most symptomatic chronic occlusions are treated with guideline-directed medical therapy while revascularization is reserved to provide symptom relief in those with refractory symptoms despite medical therapy. Subacute coronary occlusions (SCOs), a group that historically has not been well defined, are positioned in the grey zone between these extremes, yet pose significant clinical challenges and require case-by-case assessment. This review explores the nuances of managing SCOs, highlighting the importance of tailored strategies for each clinical context.","PeriodicalId":11976,"journal":{"name":"European Heart Journal","volume":"5 1","pages":""},"PeriodicalIF":39.3,"publicationDate":"2026-01-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145907552","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
扫码关注我们
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号